Latest Headlines

Latest Headlines

Another one bites the dust: Merck cans hep C fighter Victrelis as new meds take flight

Merck will stop selling Victrelis in the U.S. by the end of this year. The company cites "advances in treatment practices"--namely, the new all-oral drug cocktails offered by Gilead and AbbVie--and the shrinking demand they've caused.

Merck CEO assures shareholders there is life after death of Singulair patent

With its $5.5 billion seller Singulair going off patent in two months, things will be a little dicey for the next couple of years at Merck.

CDC delivers gift to hep C drugmakers

The recommendation by the CDC that the 70 million U.S. baby boomers all be tested for hepatitis C is a big gift for the newest hep C treatments.

Merck says Victrelis can interfere with HIV meds

Merck ($MRK) has notified doctors that its new hepatitis C drug Victrelis interferes with commonly used AIDS drugs. Victrelis can reduce the effectiveness of the HIV-fighters--and vice-versa--Merck...

Merck CEO Frazier: 'The future of the industry is going to be more partnerships'

Merck ($MRK) CEO Kenneth Frazier is deploying his deal team this year with some very specific instructions to step up their game. Speaking to an investor group, the CEO made it clear that the pharma...

Hep C smackdown: Vertex at $420M, Merck at $31M

It's convenient for hepatitis C market-watchers that Vertex Pharmaceuticals ($VRTX) and Merck ($MRK) reported their earnings less than 24 hours apart. There's no need to speculate about how the two

Merck: Don't declare a hep C victor yet

Merck ($MRK) released its first sales numbers for hepatitis C newbie Victrelis, confirming that rival Vertex Pharmaceuticals ($VRTX) is in the lead. Merck's drug brought in $21 million for the

Incivek storms hep C market with $75M launch

There's no doubt that the hepatitis C market was waiting for Incivek. In its first five weeks on the market, the Vertex Pharmaceuticals drug reaped nearly $75 million in sales. That's more than twice

Merck gets Roche to sell HCV drug in EU, elsewhere

The showdown for marketing new oral drugs against hepatitis C is getting hotter. On the heels of gaining EU approval of HCV drug Victrelis (boceprevir), Merck ($MRK) has inked a new deal with Swiss

Vertex jumps on early hep C scrip numbers

This could be the drug industry version of Hollywood's first-weekend box office revenues. Vertex Phamaceutical shares spiked on preliminary numbers showing that its new hepatitis C drug is outpacing